The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’

Publication date: May 2018
Source:European Journal of Cancer, Volume 94
Author(s): Patrick Schöffski, Agnieszka Wozniak, Michael G. Leahy, Steinar Aamdal, Piotr Rutkowski, Sebastian Bauer, Stephan Richter, Viktor Grünwald, Maria Debiec-Rychter, Raf Sciot, Birgit Geoerger, Sandrine Marréaud, Sandra Collette, Axelle Nzokirantevye, Sandra J. Strauss
BackgroundAlveolar rhabdomyosarcomas (ARMSs) can harbour MET and anaplastic lymphoma kinase (ALK) alterations. We prospectively assessed crizotinib in patients with advanced/metastatic ARMS.MethodsEligible patients with a central diagnosis of ARMS received oral crizotinib 250 mg twice daily. Patients were attributed to MET/ALK+ or MET/ALK− subcohorts by assessing the presence or absence of the forkhead box O1 (FOXO1; a marker of MET upregulation) and/or ALK gene rearrangement. The primary end-point was the objective response rate (ORR). Secondary end-points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), progression-free rate (PFR), overall survival (OS) and safety.FindingsNineteen of 20 consenting patients had centrally confirmed ARMS. Molecular assessment revealed rearrangement of FOXO1 in 17 tumours and ALK in none. Thirteen eligible patients were treated, but only eight were evaluable for the primary end-point because of the observed aggressiveness of the disease. Among seven evaluable MET+/ALK− patients, only one achieved a confirmed partial response (ORR: 14.3%; 95% confidence interval [CI]: 0.3–57.8) with a DOR of 52 d. Further MET+/ALK− efficacy end-points were DCR: 14.3% (95% CI: 0.3–57.8), median PFS: 1.3 months (95% CI: 0.5–1.5) and median OS: 5.6 months (95% CI: 0.7–7.0). The remaining MET+/ALK− and MET−/ALK− patients had early progression as best response. Common treatment-related adverse events were fatigue (5/13 [38.5%]), nausea (4/13 [30.8%]), anorexia (4/13 [30.8%]), vomiting (2/13 [15.4%]) and constipation (2/13 [15.4%]). All 13 treated patients died early because of progressive disease.InterpretationCrizotinib is well tolerated but lacks clinically meaningful activity as a single agent in patients with advanced metastatic ARMS. Assessing single agents in aggressive, chemotherapy-refractory ARMS is challenging, and future trials should explore established chemotherapy ± investigational compounds in earlier lines of treatment.Clinical Trial NumberEORTC 90101, ClinicalTrials.gov NCT01524926.



http://ift.tt/2FSz6bm